Ekso Bionics Holdings Inc (EKSO) Return on Assets ROA from the first quarter of 2026 to first quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Ekso Bionics Holdings Inc   (NASDAQ: EKSO)


Ekso Bionics Holdings Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Ekso Bionics Holdings Inc 's ROA in the first quarter of 2026?
Ekso Bionics Holdings Inc recorded a cumulative net loss of $-16 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -16.2%.

However, within the Capital Goods sector 268 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 4151, from total ROA ranking in the fourth quarter of 2025 at 4598.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Total Assets Change 1306.63 % -27.98 % -18.42 % -25.84 % -14.15 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -16 -12 -10 -11 -11
Return On Assets (TTM) -16.2 % -55.29 % -45.24 % -45.81 % -41.37 %
EKSO's Total Ranking # 4151 # 4598 # 3928 # 3974 # 4012
Total Assets (TTM) in million 326 20 20 22 23
Seq. Total Assets Change 1556.87 % -2.2 % -7.16 % -6.5 % -15.17 %
Seq. Net Income Change - - - - -

EKSO's 5 Years Annual ROA >> Back to EKSO Management Effectiveness >> Compare EKSO ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 100
Sector # 269
Overall # 4115

Return On Assets Statistics
High Average Low
179.98 %
-101.08 %
-1535.33 %
(Mar 31 2015)   (Mar 31 2014)



  News about Ekso Bionics Holdings Inc Return on Assets ROA

Ekso Bionics Sets the Stage for Record Revenues in Q4 2024 Amidst Strategic Financing Initiatives

In an impressive display of perseverance and innovation, Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) has made significant strides in its financial trajectory and product development. The company recently reported preliminary results indicating a remarkable upward trend in revenues for the fourth quarter of 2024, projecting an all-time high that positions it as a leader in the exoskeleton technology sector. This announcement comes amid a strategic fundraising initiative designed to empower the future of mobility through enhanced exoskeleton technology.Earlier in August 2024, Ekso Bionics executed a public offering aimed at raising $6 million to bolster its operational capabilities. The underwritten public offering, which comprised a total of 6,000,000 units, showcased the company’s commitment to advancing its innovative technologies in the field of mobility assistance. Each unit, priced at $1.00, included not only a share of common stock but also a Series A Warrant and a Series B Warrant, creating flexible investment opportunities for stakeholders while establishing a solid financial foundation for future developments.

Ekso Bionics Makes Strides in Exoskeleton Technology with CMS Reimbursement and Accessible Healthcare Program,


Ekso Bionics Makes Strides with CMS Reimbursement and Launches EksoHealth Personal Program
Ekso Bionics Holdings Inc, a leading exoskeleton technology company, has recently announced the receipt of initial reimbursement from the Centers for Medicare and Medicaid Services (CMS) for its Ekso Indego Personal exoskeleton. This marks a significant milestone for the company as it continues to expand its reach in the healthcare industry.
The CMS reimbursement validates the efficacy and value of Ekso Bionics exoskeleton technology in improving the lives of individuals with mobility limitations. The Ekso Indego Personal is designed to provide assistance to those with spinal cord injuries and other neurological impairments, enabling them to regain mobility and independence.



Financial Statements
Ekso Bionics Holdings Inc 's Assets $ 326 million EKSO's Balance sheet
Ekso Bionics Holdings Inc 's Income $ -7 million Quarterly EKSO's Income Statement
EKSO's Income by Division See EKSO's Income by Division



Annual Return On Assets (May 31 2025)
FY 2026		 (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022
Y / Y Total Assets Change 1412.61 % -24.54 % -7.84 % -28.36 % -17.9 %
Total Assets in million 304 20 27 29 40
Y / Y Net Income Change - - - - -
Net Income in million -73 -12 -11 -15 -15
Annual Return On Assets -23.91 % -58.15 % -42.51 % -52.56 % -37.36 %

EKSO's 5 Years Annual ROA >> Back to EKSO Management Effectiveness >> Compare EKSO ROA to its Competitors



More Return On Assets Ratios
EKSO's' Return on Assets at Yahoo Finance
Industrial Machinery and Components Industry Return On Assets Trends and Statistics
Capital Goods Sector Roa Statistics
Roa Trends for overall market
EKSO's Roa Ratio versus Industrial Machinery and Components Industry, Capital Goods Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for EKSO's Competitors
Subscribers only: Roa for Ekso Bionics Holdings Inc 's Suppliers
Subscribers only: Return On Assets for EKSO's Customers

You may also want to know
EKSO's Roi EKSO's Inventory Turnover Ratio EKSO's Growth Rates EKSO's Dividend Comparisons
EKSO's Profitability Ratios EKSO's Asset Turnover Ratio EKSO's Dividend Growth
EKSO's Roe EKSO's Valuation Ratios EKSO's Financial Strength Ratios EKSO's Dividend Payout Ratio



Companies with similar Return On Assets at Mar 31 2026, within Capital Goods Sector ROA

Date modified: 2026-09-26T07:27:16+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.